|
1
|
Janeway KA, Barkauskas DA, Krailo MD,
Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R and
Marina N: Outcome for adolescent and young adult patients with
osteosarcoma: A report from the children's oncology group. Cancer.
118:4597–4605. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bacci G, Ferrari S, Longhi A, Donati D,
Manfrini M, Giacomini S, Briccoli A, Forni C and Galletti S:
Nonmetastatic osteosarcoma of the extremity with pathologic
fracture at presentation: Local and systemic control by amputation
or limb salvage after preoperative chemotherapy. Acta Orthop Scand.
74:449–454. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gobin B, Moriceau G, Ory B, Charrier C,
Brion R, Blanchard F, Redini F and Heymann D: Imatinib mesylate
exerts anti-proliferative effects on osteosarcoma cells and
inhibits the tumour growth in immunocompetent murine models. PLoS
One. 9:e907952014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arias JL: Drug targeting strategies in
cancer treatment: An overview. Mini Rev Med Chem. 11:1–17. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Santi C, Pietrabissa A, Mosca F and
Pacifici GM: Methylation of quercetin and fisetin, flavonoids
widely distributed in edible vegetables, fruits and wine, by human
liver. Int J Clin Pharmacol Ther. 40:207–212. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khanna C, Wan X, Bose S, Cassaday R, Olomu
O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The
membrane-cytoskeleton linker ezrin is necessary for osteosarcoma
metastasis. Nat Med. 10:182–186. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ren L, Hong SH, Cassavaugh J, Osborne T,
Chou AJ, Kim SY, Gorlick R, Hewitt SM and Khanna C: The
actin-cytoskeleton linker protein ezrin is regulated during
osteosarcoma metastasis by PKC. Oncogene. 28:792–802. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Zhang L, Zhang G, Li S, Duan J,
Cheng J, Ding G, Zhou C, Zhang J, Luo P, et al: Osteosarcoma
metastasis: Prospective role of ezrin. Tumour Biol. 35:5055–5059.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin LJ and Chen LT: Association between
ezrin protein expression and the prognosis of colorectal
adenocarcinoma. Mol Med Rep. 8:61–66. 2013.PubMed/NCBI
|
|
10
|
Li L, Wang YY, Zhao ZS and Ma J: Ezrin is
associated with gastric cancer progression and prognosis. Pathol
Oncol Res. 17:909–915. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lo Vasco VR, Leopizzi M, Puggioni C and
Rocca C Della: Ezrin silencing remodulates the expression of
Phosphoinositide-specific Phospholipase C enzymes in human
osteosarcoma cell lines. J Cell Commun Signal. 8:219–229. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shang X, Wang Y, Zhao Q, Wu K, Li X, Ji X,
He R and Zhang W: siRNAs target sites selection of ezrin and the
influence of RNA interference on ezrin expression and biological
characters of osteosarcoma cells. Mol Cell Biochem. 364:363–371.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang T, Zhang H, Cai SY, Shen YN, Yuan SX,
Yang GS, Wu MC, Lu JH and Shen F: Elevated SHOX2 expression is
associated with tumor recurrence of hepatocellular carcinoma. Ann
Surg Oncol. 20(Suppl 3): S644–S649. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Murugesan SR, Akiyama M, Einfeld DA,
Wickham TJ and King CR: Experimental treatment of ovarian cancers
by adenovirus vectors combining receptor targeting and selective
expression of tumor necrosis factor. Int J Oncol. 31:813–822.
2007.PubMed/NCBI
|
|
15
|
Cai G, Zhu X, Xu Y, Du X, Zhang Z, Zhang
Y, Chen T, Zhou X, Guan Z and Cai S: Case report of extrarenal
rhabdoid tumor of pelvic retroperitoneum molecular profile of
angiogenesis and its implication in new treatment strategy. Cancer
Biol Ther. 8:417–421. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goloudina AR, Demidov ON and Garrido C:
Inhibition of HSP70: A challenging anti-cancer strategy. Cancer
Lett. 325:117–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sliutz G, Karlseder J, Tempfer C, Orel L,
Holzer G and Simon MM: Drug resistance against gemcitabine and
topotecan mediated by constitutive hsp70 overexpression in vitro:
Implication of quercetin as sensitiser in chemotherapy. Br J
Cancer. 74:172–177. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sashchenko LP, Dukhanina EA, Shatalov YV,
Yashin DV, Lukyanova TI, Kabanova OD, Romanova EA, Khaidukov SV,
Galkin AV, Gnuchev NV and Georgiev GP: Cytotoxic T lymphocytes
carrying a pattern recognition protein Tag7 can detect evasive,
HLA-negative but Hsp70-exposing tumor cells, thereby ensuring
FasL/Fas-mediated contact killing. Blood. 110:1997–2004. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stangl S, Gross C, Pockley AG, Asea AA and
Multhoff G: Influence of Hsp70 and HLA-E on the killing of leukemic
blasts by cytokine/Hsp70 peptide-activated human natural killer
(NK) cells. Cell Stress Chaperones. 13:221–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zitzler S, Hellwig A, Hartl FU, Wieland F
and Diestelkötter-Bachert P: Distinct binding sites for the ATPase
and substrate-binding domain of human Hsp70 on the cell surface of
antigen presenting cells. Mol Immunol. 45:3974–3983. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishikawa M, Otsuki T, Ota A, Guan X,
Takemoto S, Takahashi Y and Takakura Y: Induction of tumor-specific
immune response by gene transfer of Hsp70-cell-penetrating peptide
fusion protein to tumors in mice. Mol Ther. 18:421–428. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamaoka A, Guan X, Takemoto S, Nishikawa M
and Takakura Y: Development of a novel Hsp70-based DNA vaccine as a
multifunctional antigen delivery system. J Control Release.
142:411–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yao Q, Zhao HY and Xie BZ: effects of
ezrin and heat shock protein 70 on apoptosis and proliferation of
human osteosarcoma cells. Orthop Surg. 7:273–280. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rácz Z and Hamar P: SiRNA technology, the
gene therapy of the future? Orv Hetil. 149:153–159. 2008.(In
Hungarian). View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wirtzfeld LA, Wu G, Bygrave M, Yamasaki Y,
Sakai H, Moussa M, Izawa JI, Downey DB, Greenberg NM, Fenster A, et
al: A new three-dimensional ultrasound microimaging technology for
preclinical studies using a transgenic prostate cancer mouse model.
Cancer Res. 65:6337–6345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang ZH, Ye Q, Hu ZQ, Ye ZQ, Yu X and Shen
GX: In vitro anti-tumor effect of CTL induced by HSP70-Id
complex-modified dendritic cells. Zhonghua Zhong Liu Za Zhi.
28:481–485. 2006.(In Chinese). PubMed/NCBI
|
